GRAALL 2024

A randomized study involving 3 cohorts to evaluate the role of new immunotherapies and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the first-line treatment of adult patients with acute lymphoblastic leukemia

Coordinating Investigator

  • Yan Beauverd

    Yan Beauverd

    Klinikleiter

Adult acute lymphoblastic leukemia (ALL) comprises three main entities: Philadelphia chromosome–positive ALL (Ph+), Philadelphia chromosome–negative B-cell precursor ALL (Ph− BCP-ALL), and T-cell ALL/lymphoblastic lymphoma (T-ALL/LBL), accounting for approximately 25%, 50%, and 25% of cases, respectively. Recent therapeutic advances have led to a reassessment of the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission, which is now generally reserved for patients at higher risk, mainly those with high and persistent levels of minimal residual disease (MRD). 

Nevertheless, 3-year event-free survival (EFS) remains limited to approximately 60–70%, highlighting the need for innovative strategies to improve disease control while reducing treatment-related toxicity. In this setting, the emergence of immunotherapies has profoundly changed the therapeutic landscape of ALL. Several agents have been approved for patients with relapsed or refractory B-cell ALL, including blinatumomab, a CD19-directed bispecific T-cell engager, which has demonstrated the ability to induce deep responses, including MRD negativity. 

The GRAALL-2024 study is a prospective, randomized, multicenter, international clinical trial structured into three cohorts corresponding to the main ALL subtypes: Ph− B-ALL, Ph+ B-ALL, and T-ALL/LBL. After a common prephase, eligible patients are assigned to one of these cohorts. The primary objective is to improve outcomes in adults with ALL through the early, frontline introduction of antibody-based therapies, notably blinatumomab in Ph− and Ph+ disease and a targeted immunotherapy approach in T-ALL, while refining the indication for allo- HSCT in first remission.

Eligibility Criteria

Inclusion criteria:

  1. Newly diagnosed ALL or T-LL according to WHO criteria.
  2. Immunophenotypic, cytogenetic, and/or molecular testing has been performed, allowing classification into one of the following cohorts: Ph+ ALL, Ph− BCP ALL, or T-ALL/LL.
  3. No prior treatment, except for corticosteroids and/or intrathecal therapy (pre-phase).

Exclusion criteria:

  1. Patients who have previously been treated for ALL with systemic chemotherapy, antibody therapy, or a tyrosine kinase inhibitor (TKI).
  2. Patients with a pre-existing primary tumor that is currently clinically relevant or requires active treatment.
  3. Pre-existing or current clinically relevant central nervous system disease.
  4. Patients with a left ventricular ejection fraction (LVEF) < 50% or another clinically significant heart condition.

Hospitals

  • HFR Freiburg - Kantonsspital
    HFR Freiburg - Kantonsspital
  • Les hôpitaux universitaires de Genève
    Les hôpitaux universitaires de Genève
  • Luzerner Kantonsspital AG
    Luzerner Kantonsspital AG
  • Universitätsspital Basel
    Universitätsspital Basel

Further Studies: Leukemia

Recruitment completed

CLL 17

A prospective, randomized, unblinded, multicenter, phase III study comparing the efficacy and safety of ibrutinib monotherapy versus time-limited therapy with venetoclax plus obinutuzumab or ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL) - CLL17

Recruitment completed

HOVON 150

A multicenter, double-blind, randomized, placebo-controlled phase 3 study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with blast excess-2, with an IDH1 or IDH2 mutation, respectively, who are eligible for intensive chemotherapy.

Recruitment completed

HOVON 155

A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit (i.e. HCT-CI ≥ 3) adult AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT- AML/high-risk MDS patients.

Recruitment completed

HOVON 156

A phase 3, multicenter, open-label, randomized, study of Gilteritinib versus Midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.

HOVON 173

Ivosidenib and azacitidine with or without venetoclax in adult patients with newly diagnosed IDH1-mMutated AML or MDS/AML considered ineligible for intensive chemotherapy

HOVON 177

A study to investigate the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not been previously treated and are not eligible for intensive chemotherapy

HOVON 181

A study investigating the effect of adding bleximenib to standard treatment with intensive chemotherapy in patients with a specific form of acute myeloid leukemia (AML)